Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More?

Ying X Gue¹, Diana A Gorog^{2

3}, Gregory Y H Lip^{1

4}

Affiliations

¹ Liverpool Centre for Cardiovascular Science, Liverpool Heart & Chest Hospital, University of Liverpool, Liverpool, United Kingdom.
² School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom.
³ Faculty of Medicine, National Heart & Lung Institute, Imperial College, London, United Kingdom.
⁴ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Comment

Ying X Gue et al. JAMA Cardiol. 2022.

. 2022 Aug 1;7(8):794-795.

doi: 10.1001/jamacardio.2022.1572.

Ying X Gue¹, Diana A Gorog^{2

3}, Gregory Y H Lip^{1

4}

¹ Liverpool Centre for Cardiovascular Science, Liverpool Heart & Chest Hospital, University of Liverpool, Liverpool, United Kingdom.
² School of Life and Medical Sciences, Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom.
³ Faculty of Medicine, National Heart & Lung Institute, Imperial College, London, United Kingdom.
⁴ Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

No abstract available

Comment on

Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial.
Naito R, Miyauchi K, Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H; AFIRE Investigators. Naito R, et al. JAMA Cardiol. 2022 Aug 1;7(8):787-794. doi: 10.1001/jamacardio.2022.1561. JAMA Cardiol. 2022. PMID: 35704345 Free PMC article. Clinical Trial.